Electronic Clinical Decision Support for Middle Eastern Hospitals

First DataBankHospitals in the Middle East are set to benefit from sophisticated electronic clinical decision support following the commercial agreement between First DataBank International (FDB International) and GE Healthcare (GE). This agreement builds on the relationship which First DataBank has with GE Healthcare's Information Technology business in the US.

GE's Centricity® Enterprise, will provide Middle Eastern customers with electronic dispensing and prescribing functionality, with clinical decision support enabled by the integration of FDB International's drug knowledge base. Healthcare providers can use Centricity® Enterprise to help verify the medication about to be prescribed or dispensed to a patient against the patient's profile. On-screen alerts help a provider to determine if there may be a potential drug interaction, duplicate therapy, sensitivity, contraindication or precaution.

Centricity® Enterprise is an integrated clinical, financial and administrative system that helps caregivers provide enhanced patient care through computerized physician order entry (CPOE), clinical decision support and expert rules, while documenting all aspects of patient care. The system integrates core clinical processes for orders, results, pharmacy and care documentation, in concert with administrative/financial processes for scheduling, registration/admitting, charging and billing.

"This agreement gives us access to invaluable information which will immediately benefit our product," said Juergen Reyinger, EMEA vice president and general manager of GE Healthcare IT. "We look forward to working with First DataBank International in growing our solution and benefiting from their strengths, just as they will surely benefit from ours."

David Flavell, President, FDB International adds: "The Middle East is a key region in our international expansion plans as its healthcare systems are developing so rapidly. Our agreement with GE is significant as it will bring more advanced clinical decision support to hospitals in the region, helping providers to enhance patient safety by helping them reduce the occurrence of medical errors."

First DataBank continues to expand its global presence with customers across the Middle East, Asia Pacific, Australasia, Africa and Europe as well as continuing to grow its long established North American and UK markets.

About First DataBank
First DataBank (FDB) is the world's leading provider of drug knowledge bases and active clinical decision support. With over 30 years' experience of maintaining, developing and integrating drug knowledge bases across the entire healthcare spectrum, FDB has unrivalled expertise and knowledge in this specialist field. NHS Connecting for Health has chosen FDB to provide drug-related clinical decision support.

Patient safety is the driving force behind our business. Through the effective integration of our products into clinical systems, we enable safer prescribing, dispensing and administration.

For further information visit www.firstdatabank.co.uk.

About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease. For further information visit www.gehealthcare.com.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...